Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center.

IF 2.1 4区 医学 Q3 PHARMACOLOGY & PHARMACY American Journal of Health-System Pharmacy Pub Date : 2024-10-23 DOI:10.1093/ajhp/zxae096
Lorraine De La Riva, Emily Gray, Natalea Braden-Suchy, Adriane N Irwin
{"title":"Assessing provider knowledge of the federal 340B Drug Pricing Program in a federally qualified health center.","authors":"Lorraine De La Riva, Emily Gray, Natalea Braden-Suchy, Adriane N Irwin","doi":"10.1093/ajhp/zxae096","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The 340B Drug Pricing Program is important to healthcare organizations that serve vulnerable communities. However, it is unknown whether healthcare providers in these organizations understand the 340B program and how it supports enhanced patient services. This study aims to characterize the knowledge, attitudes, and beliefs of healthcare providers toward the 340B program in a multisite federally qualified health center (FQHC).</p><p><strong>Methods: </strong>This was a cross-sectional study. A 27-item survey designed to assess prescriber knowledge and perspectives toward the 340B program was developed and administered. Closed-ended items were summarized using descriptive statistics, and open-ended items were analyzed with qualitative methods.</p><p><strong>Results: </strong>A total of 198 healthcare providers with prescribing authority received the survey; of those, 65 (32.8%) participated. The majority of respondents (66.2%) were female; 41.5% were 35 years of age or younger, and 49.2% were physicians. The majority of respondents agreed that patients benefited from access to the organization's 340B pharmacies (95.0%) and that 340B pricing is important to consider when prescribing medications (78.3%). However, knowledge of the 340B program was limited, with only half of respondents (54.0%) able to correctly answer at least 4 of 7 knowledge-focused items. Reponses to a patient case suggested that some providers may be unfamiliar with which drugs are available at reduced prices.</p><p><strong>Conclusion: </strong>The findings suggest that providers believe the 340B program benefits patients and the organization but often lack a complete understanding of the program. Future research should focus on prescriber education as a strategy to help organizations optimize their 340B programs and facilitate patient access to medications.</p>","PeriodicalId":7577,"journal":{"name":"American Journal of Health-System Pharmacy","volume":" ","pages":"e692-e699"},"PeriodicalIF":2.1000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Health-System Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ajhp/zxae096","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: The 340B Drug Pricing Program is important to healthcare organizations that serve vulnerable communities. However, it is unknown whether healthcare providers in these organizations understand the 340B program and how it supports enhanced patient services. This study aims to characterize the knowledge, attitudes, and beliefs of healthcare providers toward the 340B program in a multisite federally qualified health center (FQHC).

Methods: This was a cross-sectional study. A 27-item survey designed to assess prescriber knowledge and perspectives toward the 340B program was developed and administered. Closed-ended items were summarized using descriptive statistics, and open-ended items were analyzed with qualitative methods.

Results: A total of 198 healthcare providers with prescribing authority received the survey; of those, 65 (32.8%) participated. The majority of respondents (66.2%) were female; 41.5% were 35 years of age or younger, and 49.2% were physicians. The majority of respondents agreed that patients benefited from access to the organization's 340B pharmacies (95.0%) and that 340B pricing is important to consider when prescribing medications (78.3%). However, knowledge of the 340B program was limited, with only half of respondents (54.0%) able to correctly answer at least 4 of 7 knowledge-focused items. Reponses to a patient case suggested that some providers may be unfamiliar with which drugs are available at reduced prices.

Conclusion: The findings suggest that providers believe the 340B program benefits patients and the organization but often lack a complete understanding of the program. Future research should focus on prescriber education as a strategy to help organizations optimize their 340B programs and facilitate patient access to medications.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
评估联邦合格医疗中心的医疗服务提供者对联邦 340B 药品定价计划的了解程度。
免责声明:为了加快文章的出版速度,AJHP在接受稿件后会尽快在网上发布。被录用的稿件已经过同行评审和校对,但在进行技术格式化和作者校对之前会在网上发布。目的:340B 药品定价计划对服务于弱势社区的医疗机构非常重要。然而,这些机构中的医疗服务提供者是否了解 340B 计划以及该计划如何支持增强患者服务尚不得而知。本研究旨在了解一个多地点联邦合格医疗中心(FQHC)的医疗服务提供者对 340B 计划的认识、态度和信念:这是一项横断面调查。开发并实施了一项包含 27 个项目的调查,旨在评估开药者对 340B 计划的了解和看法。采用描述性统计方法对封闭式项目进行总结,采用定性方法对开放式项目进行分析:共有 198 名拥有处方权的医疗服务提供者收到了调查问卷;其中 65 人(32.8%)参与了调查。大多数受访者(66.2%)为女性;41.5%的受访者年龄在 35 岁或以下,49.2%的受访者为医生。大多数受访者都认为,患者可以从机构的 340B 药房中受益(95%),并且在开处方时必须考虑 340B 定价(78.3%)。但是,受访者对 340B 计划的了解有限,只有一半的受访者(54%)能够正确回答 7 个知识点中的至少 4 个。对一个病人案例的回答表明,一些医疗服务提供者可能不熟悉哪些药品可以降价销售:研究结果表明,医疗服务提供者认为 340B 计划有利于患者和医疗机构,但往往对该计划缺乏全面了解。未来的研究应将重点放在开药者教育上,将其作为帮助医疗机构优化 340B 计划并促进患者获得药物的一种策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.90
自引率
18.50%
发文量
341
审稿时长
3-8 weeks
期刊介绍: The American Journal of Health-System Pharmacy (AJHP) is the official publication of the American Society of Health-System Pharmacists (ASHP). It publishes peer-reviewed scientific papers on contemporary drug therapy and pharmacy practice innovations in hospitals and health systems. With a circulation of more than 43,000, AJHP is the most widely recognized and respected clinical pharmacy journal in the world.
期刊最新文献
Recent and anticipated novel drug approvals (4Q 2024 through 3Q 2025). A call to action: Studying the shortened duration of ceftriaxone for inpatient management of acute uncomplicated cystitis. Impact of a pharmacist-led intervention on prostate cancer illness perception. Pharmacotherapy considerations for pediatric acute agitation management in the emergency department. Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1